期刊文献+

AC群脑膜炎球菌多糖结合疫苗的制备 被引量:2

Preparation of groups A and C meningococcal polysaccharide conjugate vaccine
原文传递
导出
摘要 目的 制备以B群脑膜炎球菌外膜蛋白(outer membrane protein,OMP)为载体的AC群脑膜炎球菌多糖(polysaccharide,PS)结合疫苗(AC-OMP),并初步研究该制备工艺的稳定性.方法 将以溴化氰活化的A、C群PS分别与B群OMP偶联制成AC-OMP.按《中华人民共和国药典》2010年版三部的要求对制备的AC-OMP进行检定.以制备的AC-OMP免疫小鼠,用ELISA法检测小鼠血清抗体阳转率.结果 制备的AC-OMP的各项指标均达到质控标准.AC-OMP具有良好的免疫原性,AC-OMP免疫小鼠的血清抗PS抗体阳转率为100%.结论 该工艺适用于AC-OMP制备. Objective To prepare groups A and C meningococcal polysaccharide (PS) conjugate vaccine with outer membrane protein (OMP) of group B meningococcus as a carrier (AC-OMP),and preliminarily study on stability of the preparation process for AC-OMP.Methods Groups A and C meningococcal polysaccharides activated by cyanogen bromide were coupled with OMP of group B meningococcus respectively to prepare monovalent A-OMP and C-OMP,then AC-OMP was prepared by mixing monovalent A-OMP and C-OMP.The prepared AC-OMP was detected according to the requirements of Chinese Pharmacopoeia 2010 (Volume Ⅲ).Mice were immunized with the prepared AC-OMP,and seroconversion rates of anti-PS in immunized mice were detected by ELISA.Results Each index of the prepared AC-OMP achieved quality control standard.AC-OMP had a good immunogenicity,and seroconversion rates of anti-PS were 100% in immunized mice.Conclusion The preparation process is suitable for AC-OMP.
出处 《国际生物制品学杂志》 CAS 2013年第6期281-283,共3页 International Journal of Biologicals
关键词 奈瑟球菌 脑膜炎 疫苗 结合 多糖类 细菌 细菌外膜蛋白类 Neisseria meningitidis Vaccines, conjugate Polysaccharides, bacterial Bacterial outer membrane proteins
  • 相关文献

参考文献8

二级参考文献53

  • 1刘方蕾,吴兵,杜琳,杨淼,王志军,杨福军,罗广.A群奈瑟氏脑膜炎球菌荚膜多糖-破伤风类毒素结合疫苗的制备及其免疫原性研究[J].微生物学免疫学进展,2005,33(2):14-20. 被引量:8
  • 2Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing[J]. Science, 2000, 287(5459):1816-1820. 被引量:1
  • 3Maurizio C, Stefania B, Brunella B, et al. NadA, a Novel Vaccine Candidate of Neisseria meningitidis[J].J Exper Med, 2002, 195(11): 1445-1454. 被引量:1
  • 4Poolrnan J, Berthet FX. Alternative vaccine strategies to prevent serogroup B meningocoecal diseases[J]. Vaccine, 2001, 20(Suppl 1): 24-26. 被引量:1
  • 5Marzia MG, Jeannette A, Maurizio C, et al. A universal vaccine for serogroup B meningococcus[J]. PNAS, 2006, 103(29),10834-10839. 被引量:1
  • 6Caugant DA, Hoiby EA, Magnus P, et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population[J]. Clin Microbiol, 1994, 32(2): 323-330. 被引量:1
  • 7Hayrinen J, Jennings H, Raff HV, et aL Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides[J]. J In fect Dis, 1995,171 (6): 1481-1490. 被引量:1
  • 8Finne J, Bitter-Suermann D, Goridis C, et al. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues[J]. J Immunol, 1987, 138 (12): 4402-4407. 被引量:1
  • 9Poolman JT, Lind I, Jonsdottir K, et al. Meningococcal serotypes and serogroup B disease in Northwest Europe[J]. Lancet, 1986, 2 (8506):555-558. 被引量:1
  • 10Sacchi CT, Lemos APS, Popovic T, et al. Serosubtypes and PorA Types of Neisseria meningitidis Serogroup B Isolated in Brazil during 1997-1998: Overview and Implications for Vaccine Development[J]. J Clin Microbiol, 2001, 39(8) : 2897-2903. 被引量:1

共引文献8

同被引文献11

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部